Based on evidence and experience, countries worldwide are adding the option of DMPA-SC self-injection to their contraceptive method mix.
Self-injection has the potential to reduce access-related barriers for women, increase contraceptive continuation rates, and enhance women’s autonomy. There are strong data that women, including women in low-resource settings, can self-administer DMPA-SC safely and effectively, and that they like doing so.
This checklist is a customizable tool that can be used to monitor Subcutaneous DMPA (DMPA-SC, Sayana® Press) contraceptive self-injection programs and health worker practices. The questions can be adapted as needed to align with local program designs and guidelines. To access the MS Word version of this tool in English or French, please email FPoptions@path.org.
This brief summarizes recent evidence from African countries on the costs and cost-effectiveness of DMPA-SC. Key findings include that DMPA-SC may help reduce service delivery costs by catalyzing expansion of channels closest to women and that self-injected DMPA-SC is cost-saving as compared to clinic-administered DMPA-IM when accounting for costs to women and health systems.
In 2019, the Evidence to Practice meeting provided an opportunity to sustain progress and ensure that women have access to this contraceptive innovation as quickly as possible. Delegates from 20 countries across Africa and Asia attended sessions on the state of global scale-up, self-injection evidence and best practices, family planning and HIV integration, the role of the private sector, skills building (monitoring, learning, and evaluation; commodity forecasting; and advocacy), demand generation, innovative training approaches, and a conversation with five DMPA-SC donors.